Bank of America
ALGS icon

Bank of America’s Aligos Therapeutics ALGS Stock Holding History

Bank of America’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.71M Buy
229,754
+216,646
+1,653% +$1.64M ﹤0.01% 4216
2025
Q4 		$122K Buy
13,108
+11,194
+585% +$106K ﹤0.01% 5548
2025
Q3 		$18.8K Sell
1,914
-698
-27% -$6.38K ﹤0.01% 7078
2025
Q2 		$18.8K Sell
2,612
-151,891
-98% -$909K ﹤0.01% 7071
2025
Q1 		$1.27M Buy
154,503
+154,218
+54,112% +$3.38M ﹤0.01% 5058
2024
Q4 		$11.4K Sell
285
-6,566
-96% -$127K ﹤0.01% 6948
2024
Q3 		$59.3K Sell
6,851
-25,790
-79% -$321K ﹤0.01% 6497
2024
Q2 		$286K Sell
32,641
-13,268
-29% -$233K ﹤0.01% 5693
2024
Q1 		$1.12M Sell
45,909
-1
-0% -$20 ﹤0.01% 4863
2023
Q4 		$762K Sell
45,910
-99
-0.2% -$1.7K ﹤0.01% 5189
2023
Q3 		$859K Sell
46,009
-29
-0.1% -$643 ﹤0.01% 4926
2023
Q2 		$1.12M Buy
46,038
+127
+0.3% +$3.41K ﹤0.01% 4697
2023
Q1 		$1M Sell
45,911
-95
-0.2% -$3.63K ﹤0.01% 4894
2022
Q4 		$1.09M Buy
46,006
+80
+0.2% +$2.02K ﹤0.01% 4778
2022
Q3 		$1.26M Buy
45,926
+415
+0.9% +$13.8K ﹤0.01% 4690
2022
Q2 		$1.38M Sell
45,511
-1,859
-4% -$63.1K ﹤0.01% 4621
2022
Q1 		$2.55M Buy
47,370
+798
+2% +$63.9K ﹤0.01% 4351
2021
Q4 		$13.8M Buy
46,572
+45,223
+3,352% +$16.5M ﹤0.01% 2597
2021
Q3 		$522K Buy
1,349
+679
+101% +$269K ﹤0.01% 5610
2021
Q2 		$341K Sell
670
-110
-14% -$70.1K ﹤0.01% 5707
2021
Q1 		$444K Buy
780
+436
+127% +$290K ﹤0.01% 5468
2020
Q4 		$237K Buy
+344
New +$168K ﹤0.01% 5490

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Bank of America's ALGS Position: Q1 2026 in Review

Bank of America increased its Aligos Therapeutics (ALGS) stake by 1,653% in Q1 2026, buying an estimated $1.64M and bringing the position to 229,754 shares worth $1.71M. The position accounts for ﹤0.01% of the portfolio, ranked #4216.

Bank of America first reported a position in ALGS in Q4 2020 and has held it in 22 quarters since. The position peaked at $13.8M in Q4 2021. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

  • Bank of America held 229,754 shares of Aligos Therapeutics worth $1.71M as of Q1 2026.
  • Bank of America bought 216,646 Aligos Therapeutics shares in Q1 2026, an estimated $1.64M.
  • Aligos Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4216 holding.
  • Bank of America first reported a position in Aligos Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Bank of America's Aligos Therapeutics position peaked at $13.8M in Q4 2021.
  • 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.